Physician profile
Robert L Fallstrom
NPI 1922033604
$4,278.17
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,782 · 2020: $1,018 · 2021: $1,295 · 2022: $166 · 2024: $17.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $17.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $17.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,160.59 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $427.35 | 2019-2021 | |
| Pfizer INC. | $419.92 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $359.57 | 2019-2021 | |
| Novo Nordisk INC | $341.88 | 2019-2022 | |
| Lilly USA, LLC | $332.43 | 2019-2021 | |
| Glaxosmithkline, LLC. | $229.67 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $168.99 | 2019-2022 | |
| Abbvie INC. | $138.22 | 2021-2022 | |
| Amgen INC. | $102.73 | 2019-2020 | |
| Mylan Specialty L.P. | $90.93 | 2019-2020 | |
| Janssen Biotech, INC. | $85.74 | 2019 | |
| Merck Sharp & Dohme LLC | $58.22 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.34 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $33.39 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $29.58 | 2020-2021 | |
| Abbott Laboratories | $24.15 | 2022 | |
| Supernus Pharmaceuticals, INC. | $23.29 | 2020 | |
| Amarin Pharma, INC. | $21.55 | 2020 | |
| Sunovion Pharmaceuticals INC. | $20.55 | 2022 | |
| Grifols USA, LLC | $18.75 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.35 | 2020 | |
| Baxter Healthcare | $17.74 | 2024 | |
| Phadia US INC. | $17.71 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.91 | 2020 | |
| Novartis Pharmaceuticals Corporation | $16.88 | 2021 | |
| Avanir Pharmaceuticals, INC. | $15.97 | 2019 | |
| Sanofi Pasteur INC. | $13.56 | 2021 | |
| Shire North American Group INC | $11.62 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.59 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fallstrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.